To the editor: Jakubowiak et al recently published promising results from a phase 1/2 study evaluating the second-generation proteasome inhibitor carfilzomib in combination with lenalidomide and dexamethasone (CRd) for the treatment of newly diagnosed multiple myeloma.[1][1] Encouragingly, only 23
No takes yet. Share an insight, caveat, or question.
Voorhees et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: